SureTrader Advertisement SureTrader
Home > Boards > US OTC > Food - Processing and Agriculture >

Plandai Biotechnology, Inc. (PLPL)

PLPL RSS Feed
Add PLPL Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 5/2/2016 10:05:09 AM - Followers: 173 - Board type: Free - Posts Today: 2


www.plandaibiotech.com

Movie by Plandai:
http://vimeo.com/95723836









Interview of CEO (Audio / February 14, 2012)
http://thestockradio.com/plpl-plandai-biotechnology-inc-v-p-global-director-of-marketing-sales-callum-baylis-duffield/

 
 

Security Details

 

Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view.  

www.otcmarkets.com

  A/S :        500 million confirmed / State of Nevada
  O/S :                              134.300.000 (Febr. 6th, 2015)
                                        160.520.000 (Oct. 1st, 2015
Free Float:                     66.300.000 (Febr. 6th, 2015)
                                  ? in oct. 2015

Incorporated in: NV,USA - Year of Inc.:  2012

                                                                                                                                                                                                                   Transfer Agent

Signature Stock Transfer, Inc., Transfer Agent, 2632 Coachlight Ct., Plano, TX, 75093, 972-612-4120

SignatureStock@aol.com


http://www.anneslie.org/times/News_icon.jpg

JUNE 29, 2015
Plandai Biotechnology Enters Into Agreement to Supply Phytofare to United Kingdom Distributor With First Purchase Order

GOODYEAR, AZ--(Marketwired - June 29, 2015) - Plandaí Biotechnology, Inc. (PLPL) (“Plandaí” or “the Company”), producer of the highly bioavailable green tea extract, Phytofare® Catechin Complex, today announced that it has entered into an agreement with ProTec Nutra (“ProTec”), a leading supplier of high quality ingredients to the European food and nutraceutical industry, to become the official distributor of the Company’s Phytofare® Catechin Complex in the United Kingdom (UK). ProTec has placed its first order for Plandaí’s Phytofare® Catechin Complex to fill confirmed orders that ProTec has received from its client base in the UK.

ProTec sources, develops and markets specialty ingredients and bulk products into the Functional Foods and Nutraceuticals markets in Europe with a number of manufacturing partners including Plandaí Biotechnology: www.protecnutra.com/our-partners/plandai-biotechnology.

Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí, said, “Having a distributor with an ethos of quality and the customer base that ProTec does, shows our intention to supply our products to companies that specialize in high quality, branded ingredients. This also reaffirms our aim to become THE supplier of highly bioavailable extracts in the marketplace. ProTec has shown a complete understanding of what we’re bringing to the market and has managed to translate this into immediate sales in the United Kingdom. I fully expect sales to increase exponentially in the coming months due to their tireless work to promote only the highest quality ingredients.”

Gary Parker is the Sales Manager for ProTec Nutra and when commenting on what separates Plandaí’s Phytofare® from other green tea extracts he said, “ProTec Nutra is committed to looking for new and innovative nutritional ingredients. A Green Tea that is ‘so different’ to the Green Tea currently dominating the health food industry is a revelation. Phytofare® quite simply ‘ticks all the boxes.’ It’s actually ‘green,’ it’s not from China, it’s backed by clinical studies and with 10x the bioavailability of a generic Green Tea, the consumer gets a product that really works and the ‘cost per dose’ is significantly lower. Beat that!”

ProTec Nutra is part of the London Pharma & Chemicals Group, Ltd. (LPC) companies (www.lpc-grp.com), a privately owned group with over 30 years of experience and offices in eight countries. LPC specializes in the supply, promotion and distribution of specialty ingredients and pharmaceutical products.



Plandai Biotechnology, Inc. Signs Agreement to Become Exclusive Supplier to USN

LOGAN, UT--(Marketwired - May 11, 2015) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí” or “the Company”), producer of the highly bioavailable Phytofare® catechin complex, today announced its entry into an exclusive 3 year supply agreement with USN Worldwide. Pursuant to the contract, the Company will initially sell to USN commercial amounts of Phytofare® catechin complex for USN’S South African markets. Ultimately, the parties intend to expand USN’s purchases globally into other territories in which USN operates.

USN (www.usn.co.za) was founded in South Africa in 2000, and it remains a comprehensive health and nutrition supplement brand, driving the forefront of sports nutrition globally. Rapid expansion and an increasing consumer base have been realized through a commitment to leading product innovation, the highest quality raw material suppliers globally, premium manufacturing facilities and excellent customer support on all levels. All products are formulated with the backing of extensive research and scientific findings, as well as the important clinical trials to ensure efficacy and safety. USN continues its global growth strategy, and it is now being sold in pharmacies, FMCG and specialist retailers in over 53 countries on four continents.

This agreement also allows USN to further control the input costs around production, while enhancing product efficacy by replacing the generic green tea extracts in its extensive stable of innovative and market leading products, with the clinically proven highly bioavailable Phytofare® catechin complex. This agreement gives Plandai the opportunity to cement its relationship with a long-term global customer who has a vision for growth and market expansion.

Callum Baylis-Duffield, Vice President of Sales and Marketing for Plandaí, commented, “We are extremely pleased to enter into this agreement with a company that has the remarkable reputation of USN. As a leader in sports nutrition, they understand the benefits of phyto-availability within their product line-up, as well as the need to ensure that customers are getting the maximum potential and benefit from their supplements. Such a brand can only continue its innovative streak and fantastic track record.”

Irma Botes, Head of Research and Development at USN, added, “Establishing long-term relationships with a supplier like Plandaí is an important part of ensuring that we remain at the forefront of our industry. Customers are demanding more and more from their bodies and from their nutrition supplement partner, and USN remains committed to providing the best products to the global market place. Phytofare®, by focusing on both absorption and residence in the body, using all natural botanicals, gives us a huge competitive advantage -- an advantage we’re confident our customers will notice in their performance and overall health.”

USN Founder and CEO, Albe Geldenhuys commented, "Our industry is continually progressing with respect to product innovation and scientific findings. Establishing long-term relationships with leading suppliers globally ensures that our brand embraces the innovation and the science that drives this industry, cementing our position as a global leader. This agreement is a commitment to a mutual investment that will see further product improvements in our offering this year and well into the future."


   Plandai Biotechnology, Inc.'s CEO Discusses Company's Plans for 2015____________________________________

NEW YORK, NY--(Marketwired - January 09, 2015) - Plandaí Biotechnology (PLPL) recently updated shareholders on a list of accomplishments reached in 2014, so Stock Market Media Group (SMMG), a research and content development investment relations firm, spoke with Plandaí's Chief Executive Officer, Roger Duffield, to discuss Plandaí's plans for 2015.

SMMG: First and foremost, can we get your reaction to the opening of your new production facility in South Africa and what does its completion mean for Plandaí in 2015?

Roger Duffield: "Well, opening the Senteeko facility is really the culmination of over a decade of research, sacrifice, and determination. Taking the initial concept that we could produce a highly bioavailable plant extract -- at a time when no one was even looking at the importance of bioavailability for nutraceuticals -- and then seeing it through to this point, has been an amazing journey that wouldn't have happened without the help and support of countless people. I get chills every time I visit Senteeko, drive thirty minutes on logging roads through thick forests, and then pass the gates to our estate and see the vast acres of tea with this amazing jewel of a factory sitting in the middle. I'm overwhelmed, excited, relieved, and deeply humbled all at the same time." 

SMMG: What is the significance of Plandaí's shift from a research and development company to a biotech that produces and sells products?

Roger Duffield: "Let me answer by first stating that Plandaí will always be a research and development company. When you look at the pharmacopeia of medicinal plants, you can see that there are hundreds of potential future research products for us. And even with just green tea catechins, we could spend a lifetime just on different human clinical trials as we explore the vast potential of this amazing plant.

"But, from a practical standpoint, now that the factory is opened, we can start generating revenues and positive cash flows. This will allow us to operate without dilution or incurring additional debt, expand our products lines, and return value to our shareholders. "Operationally, it means that we now have a whole new business model with new logistics. When you stop to think about what it takes to sell a product like Phytofare®, it requires so many moving parts working in harmony. Growing the leaf, picking it properly, manufacturing, batch testing, packaging, tracking and quality control, shipping, customs. Then you have the sales aspect, which includes marketing, trade shows, literature. It's really quite a process that I think few people fully understand."

SMMG: In 2013 Plandaí announced its entrance into the cannabis research arena, in 2014, the company secured a licensing agreement with Diego Pellicer and then obtained a consent letter from the Minister of Health in Uruguay to begin growing cannabis and producing an extract for animal testing, so what can we expect in 2015?

Roger Duffield: "Our plan at this point is to establish the cannabis growing infrastructure in Uruguay this year with an expectation of having an extract ready for testing six to nine months after it comes online. Our initial goal of having a product market-ready by the end of 2014 proved unrealistic once we determined that current U.S. laws, even in states where marijuana is legalized, prohibited us from legally acquiring cannabis, producing an extract, and then testing it inside the U.S. "Our operation in Uruguay will allow us to better control the chemical profile and then conduct our research into various neural disorders in a safe, legal, and scientifically validated manner. Also, we will be able to establish standards for dosage and chemical profile, which has so far been very limited with respect to cannabis research."

SMMG: After releasing the data in 2014 from a human clinical trial performed at North West University in South Africa that showed Plandaí's Phytofare® Catechin Complex demonstrated ten times greater bioavailability over a generic catechin extract, what is next in the on-going research at North West University?

Roger Duffield: "Starting this month, the research team at North West University in South Africa, under the supervision of the Dean's office of the Faculty of Health Sciences and the inventor of the Pheroid® delivery system, Prof. Anne Grobler, will complete the third arm of the bioavailability study. This final phase will use the same 26 human subjects, but this time the study will incorporate the addition of Pheroid® to the Phytofare® extract. "We anticipate that adding the Pheroid® delivery system will increase the overall bioavailability while also opening up the potential to use our extracts in less controlled applications such as adding Phytofare® to other ingredients including topical creams and liquids, and in environments where you are less able to control exposure to outside influences such as UV light, which kills the antioxidants."North West University will also be conducting our human weight loss clinical trial, which will test the Phytofare® versus a placebo over 90 days and involving 120 patients. This trial will also be looking at a complete blood panel so we can identify from a medical standpoint the effects of catechins on everything from blood sugar to cholesterol. The results could potentially open entirely new fields of research."

SMMG: Any closing thoughts?

Roger Duffield: "2015 promises to be a productive year for Plandaí. With the completion of the new laboratory inside the Senteeko facility, we plan to produce our first citrus extract and then test its bioavailability followed by a human clinical trial to confirm improved respiratory benefits including symptom relief for sinus, colds and the flu. And, as always, we continue to explore the medical potential of other phytonutrients and expect to test new extracts throughout the year."

______________________________________________________________________________________________________________________________________________________________________________________________

For press releases please visit: www.plandaibiotech.com/press-release.html

_____________________________________________________________________________________________________________________________________________________________________________________________
 

                                                                                                                                                    PLANDAI BIOTECHNOLOGY at Africa                                                 

 

          


          

 

                                                                                                              Management Team
Roger Duffield President, Chief Executive officer and member of the Board of Directors

Callum Baylis-Duffield Vice-President and Global Director: Marketing Sales

David Rzepnicki Chief Financial Officer and member of the Board of Directors

Tim Matula Investor Relations and member of the Board of Directors

Contact:
Roger Duffield
Chief Executive Officer
Plandai Biotechnology, Inc.
1451 North 200 East, Suite 130C
Logan, UT 9810

(Validity unkown:
Corporate Headquarters Address: 2226 Eastlake Ave E, #156 Seattle, Washington, 98102, USA
Phone: (425) 466-0212
Website:              http://www.plandaibiotech.com
Email:                  Info@plandaibiotech.com

 

http://www.pub.ac.za/newsletter/02-201412/img/p-article-1-E.jpg http://www.plandaibiotech.com/blog/wp-content/uploads/2013/05/7.jpg http://www.plandaibiotech.com/blog/wp-content/uploads/2012/09/2012-08-26-12.46.231.jpg
http://www.otcjournal.com/otcb/wp-content/uploads/2013/09/factory.gif
http://www.plandaibiotech.com/blog/wp-content/uploads/2014/02/senteeko-2.jpg
http://www.plandaibiotech.com/images/senteeko-2014-02.jpg




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PLPL
Current Price
Volume:
Bid Ask Day's Range
Wiki
SureTrader
PLPL News: Current Report Filing (8-k) 04/27/2016 05:21:07 PM
PLPL News: Current Report Filing (8-k) 03/02/2016 04:23:50 PM
PLPL News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 11/16/2015 03:58:56 PM
PostSubject
#12596   Added today. jjr04001 05/02/16 10:05:09 AM
#12595   Let her flyyyy jjr04001 05/02/16 09:48:29 AM
#12594   Diego Pellicer Investment in Plandai. Roland Rick Perry 05/01/16 01:35:55 PM
#12593   90.000.000 in 2016 !!!! check: http://www.sec.gov/Archives/edgar/d Aston Martin 04/30/16 12:41:09 PM
#12592   60k in revs!!!-that helps keep the electricity on---or tmonkey 04/29/16 09:41:18 AM
#12591   I love how the mm's made this close jjr04001 04/29/16 07:58:49 AM
#12590   Plandai Biotechnology, Inc. Announces Record Sales Volume for April jjr04001 04/29/16 07:57:34 AM
#12589   Interview of Vice President does not present significant Aston Martin 04/23/16 12:35:19 PM
#12588   LOL Good joke. Aston Martin 04/19/16 11:08:40 AM
#12587   Actually, the chart is prepared for the release jjr04001 04/19/16 12:56:53 AM
#12586   You are really a little cardshaper LOL.... you Aston Martin 04/18/16 11:03:20 AM
#12585   Still trading between the middle and upper on jjr04001 04/17/16 02:12:51 PM
#12584   Just based on such fundamental news since last Aston Martin 04/14/16 12:13:27 PM
#12583   Plandai Biotechnology, Inc. Vice President Gives Online Proactive jjr04001 04/14/16 07:56:03 AM
#12582   MACD crossover! PLPL crazy bullish! stockcharts.com/c-sc/sc?s=PLPL&p=D&s jjr04001 04/13/16 12:44:20 PM
#12581   THRILLING !!!! http://ih.advfn.com/p.php?pid=webchart&btn=s_ok&s_symbol_select=USOTC%3A Aston Martin 04/11/16 01:50:38 PM
#12580   Trading nicely between the upper and middle bb jjr04001 04/10/16 04:37:05 PM
#12579   Monday it will bounce every single Friday it foreveralone 04/08/16 06:40:47 PM
#12578   thats it its going to $1 usd foreveralone 04/08/16 06:33:05 AM
#12577   hope you are not at those 95% of Aston Martin 04/07/16 04:43:21 PM
#12576   Yo you like that gapper? Guess what jjr04001 04/07/16 12:03:34 PM
#12575   I assume lots of those, who got caught Aston Martin 04/06/16 04:46:14 AM
#12574   Obviously you have a problem to understand sarcasm: Aston Martin 04/05/16 11:42:35 AM
#12573   I need a $1 a share to make foreveralone 04/05/16 11:31:50 AM
#12572   That's what you thought? Really? Fact jjr04001 04/05/16 10:04:41 AM
#12571   I thought 1.00 is an exit? ;-) However, Aston Martin 04/05/16 09:43:28 AM
#12570   Charts show hypes - hypes force buyer to Aston Martin 04/05/16 09:40:06 AM
#12569   .50 is not an entry, it's an exit. jjr04001 04/05/16 07:46:22 AM
#12568   No such thing as good fundamentals in the jjr04001 04/05/16 07:44:41 AM
#12567   If PLPL would prove by good fundamentals to Aston Martin 04/04/16 04:57:08 PM
#12566   Added .058 today. PLPL! jjr04001 04/04/16 02:04:53 PM
#12565   Well, to me this looks like going .05 Aston Martin 04/04/16 01:36:25 PM
#12564   Still between the weekly middle and upper bb jjr04001 04/03/16 08:04:14 PM
#12563   Not everybody who is critical towards pennystock chart Aston Martin 04/03/16 02:01:21 PM
#12562   Lovely trading between the weekly middle and upper jjr04001 04/03/16 11:55:45 AM
#12561   Two bull traps within two weeks. Not funny Aston Martin 04/01/16 11:28:44 AM
#12560   Poor. Pity, really. Not very promising, but for me...reasonable. Aston Martin 03/30/16 05:28:31 PM
#12559   chart today says - with 'great' news: To Aston Martin 03/30/16 11:45:27 AM
#12558   Plandai Biotechnology, Inc. Announces New Distributor to Boost jjr04001 03/30/16 07:48:32 AM
#12557   The stock is definatly in play right now. foreveralone 03/30/16 06:29:35 AM
#12556   PLPL golden cross coming! jjr04001 03/30/16 06:02:33 AM
#12555   $PLPL #6 on Top 10 OTC Advancers today! Airdawg Investments 03/29/16 11:29:24 PM
#12554   tmonkey, nobody can help gambler ;-) Every hype Aston Martin 03/29/16 09:40:57 PM
#12553   ah, just blah blah LOL...guess what would have Aston Martin 03/29/16 09:35:06 PM
#12552   RSI above 53 big play time? is someone foreveralone 03/29/16 04:05:04 PM
#12551   i see 1.3 mill vol and under 8 tmonkey 03/29/16 03:31:01 PM
#12550   infact $2 time foreveralone 03/29/16 02:17:45 PM
#12549   1mil volume its 1$ time foreveralone 03/29/16 01:28:30 PM
#12548   MACD crossover is going to take this through jjr04001 03/29/16 12:42:09 PM
#12547   bla bla bla. Technicals rule. PLPL! jjr04001 03/29/16 12:12:28 PM
PostSubject